Parenteral nutrition and insulin per protocol improve diabetes management after total pancreatectomy

Sakshi Andersen1,2, Andreas Andersen1,2, Lene Ringholm3, Carsten Palnaes Hansen4, Jan Storkholm4, Kerstin Lillpers2, Charlotte Schiøtz2 & Elisabeth Reinhardt Mathiesen1,2

ABSTRACT
INTRODUCTION: Pancreatogenic diabetes develops in patients undergoing total pancreatectomy and complicates post-surgical management. The aim of this study was to compare parenteral nutrition (PN) with protocollled insulin treatment to intravenous glucose treatment after total pancreatectomy. METHODS: This was a retrospective study of 97 patients undergoing total pancreatectomy between 2009 and 2014. Patients were divided into a PN cohort (n = 57) and a glucose cohort (n = 40). The PN cohort was given PN with one international unit (IU) rapid-acting insulin per 10 g of carbohydrate. The glucose cohort was given a continuous 5% glucose infusion with 2 IU rapid-acting insulin per 10 g of carbohydrate. Both cohorts were given insulin detemir 0.2 IU/kg/day. RESULTS: Within the first 13 post-operative days, plasma glucose values were within the target range (4.0-10.0 mmol/l) in the PN cohort more frequently than in the glucose cohort (46% versus 42%, p = 0.01) without any increase in hypoglycaemia. Non-infectious complications occurred less frequently in the parenteral cohort than in the glucose cohort (23% versus 43%, p = 0.04). Infectious complications occurred in 19% versus 33% of patients, respectively (p = 0.14). The mean length of hospitalisation was 19.8 ± 12.7 versus 25.0 ± 21.5 days, p = 0.14. CONCLUSIONS: After total pancreatectomy, PN with insulin treatment per protocol improves glycaemic control compared with glucose infusion and reduces the number of non-infectious post-operative complications without increasing hypoglycaemia. FUNDING: none. TRIAL REGISTRATION: not relevant.

Total pancreatectomy is mainly indicated for patients with pancreatic malignancy [1, 2]. The resulting pancreatogenic diabetes is characterised by hyperglycaemia, frequent episodes of hypoglycaemia during insulin treatment, but rarely by ketoacidosis [3, 4]. During insulin treatment after total pancreatectomy, patients sustain an increased risk of hypoglycaemia, especially during night time [3-5]. This susceptibility to hypoglycaemia may be aggravated by insufficient nutrition, leading to catabolism and glycogen depletion in the muscles and liver [3]. In addition to regulation of blood glucose, insulin is a major anabolic hormone, which increases protein synthesis and enhances macrophage infiltration in wounds, thus promoting tissue repair after surgery [6, 7]. Total pancreatectomy is a rare procedure performed by pioneers, while partial pancreatectomy is much more common. After partial pancreatectomy, hyperglycaemia within the first 24 hours is associated with an increased length of hospitalisation and an increased number of surgical complications [8, 9]. Post-operative parenteral nutrition (PN) is indicated where adequate enteral feeding is not expected within seven days after surgery [10]. Therefore, PN might be beneficial after major surgery, such as total pancreatectomy, although an increased prevalence of post-operative infections has also been described [11], and fear of hyperglycaemia may also be a barrier for PN. Appropriate nutrition and insulin treatment after total pancreatectomy is critical in these totally insulin-depleted patients. However, prospective randomised trials in this rare patient category are difficult to accomplish.

In our centre, the post-operative nutritional regimen after total pancreatectomy initially consisted of continuous intravenous glucose infusion based on the assumption that enteral feeding would be established within few days. However, for the majority of patients, this was not the case. In 2012, the post-operative nutritional regimen was therefore changed to include PN with insulin treatment according to a newly developed local protocol. The aim of this study was to evaluate PN with protocollled insulin treatment versus intravenous glucose treatment for its effect on glycaemic control, post-operative complications and length of hospitalisation.

METHODS
Study design
This retrospective study included 97 (92%) out of 106 patients undergoing total pancreatectomy between December 2009 and November 2014 at the Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen. Nine patients were excluded because their diabetes charts were unavailable. According to the post-operative nutritional regimen, patients were divided into two co-
The PN cohort started PN (SmofKabiven, Fresenius Kabi, Hamburg, Germany) on the first post-operative day. PN was given at a constant infusion rate over 20 hours per day. One international unit (IU) of rapid-acting insulin aspart (Novorapid, Novo Nordisk) per 10 g of carbohydrate was added to the PN. PN was administered according to preoperative body weight. Thus, patients received 125 g (40-50 kg), 187 g (51-70 kg), 250 g (71-90 kg), or 313 g (> 90 kg) of carbohydrate per day. PN was terminated when the patient had a sufficient oral daily intake of at least 150 g of carbohydrates.

The glucose cohort was treated with continuous intravenous infusion of isotonic glucose 5%, which was initiated on the first post-operative day. The infusion rate was 60 ml/hour, which is consistent with a 72-g carbohydrate intake per 24-hour period. According to local practice, 2 IU of insulin aspart was added per 10 g of carbohydrate. Only on various individual indications could patients initiate PN. Glucose infusion was terminated when a sufficient oral intake was restored.

Both cohorts had a routine 24-hour post-operative stay at the intensive care unit, where they were given individually titrated glucose-insulin infusion. When transferred to the surgical ward, the patients initiated treatment according to the post-operative nutritional regimen described above. Plasma glucose was measured at least five times daily. In order to ensure basic insulin requirements, patients were given long-acting insulin detemir (Levemir, Novo Nordisk) 0.2 IU/kg/day divided into two doses. Supplementary doses of insulin aspart were given when plasma glucose values exceeded 10 mmol/l. A meal bolus of insulin aspart (2 IU) was given when oral feeding was initiated along with protein energy drinks (2-4 IU). Supplementary digestive enzymes (Creon, Mylan) were given with every meal.

### Data sampling and management

Clinical data were obtained from the hospital records including diabetes charts. Day 0 was defined as the day of surgery. The daily median plasma glucose level for each patient was calculated. Additionally, plasma glucose values were divided into five predefined intervals and the target range was defined as a plasma glucose between 4.0-10.0 mmol/l. A meal bolus of insulin aspart (2 IU) was given when oral feeding was initiated along with protein energy drinks (2-4 IU). Supplementary digestive enzymes (Creon, Mylan) were given with every meal.

### TABLE 1

Baseline characteristics of two cohorts undergoing total pancreatectomy given routine postoperative parenteral nutrition treatment or glucose infusion, respectively.

<table>
<thead>
<tr>
<th></th>
<th>Parenteral nutrition cohort (n = 57)</th>
<th>Glucose cohort (n = 40)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men/women, n</td>
<td>30/27</td>
<td>19/21</td>
<td>0.62</td>
</tr>
<tr>
<td>Age, yrs, mean ± SD</td>
<td>65.9 ± 9.7</td>
<td>65.1 ± 7.7</td>
<td>0.67</td>
</tr>
<tr>
<td>Weight, kg, mean ± SD</td>
<td>68.7 ± 2.0</td>
<td>72.8 ± 2.7</td>
<td>0.21</td>
</tr>
<tr>
<td>BMI, kg/m², mean ± SD</td>
<td>23.5 ± 4.7</td>
<td>24.2 ± 5.3</td>
<td>0.51</td>
</tr>
<tr>
<td>Preoperative diabetes mellitus, n (%)</td>
<td>12 (21)</td>
<td>16 (40)</td>
<td>0.04</td>
</tr>
<tr>
<td>Current smokers, n (%)</td>
<td>20 (35)</td>
<td>11 (28)</td>
<td>0.55</td>
</tr>
<tr>
<td>Alcohol exceeding recommendations a, n (%)</td>
<td>9 (16)</td>
<td>6 (15)</td>
<td>0.79</td>
</tr>
<tr>
<td>Histology, n (%)</td>
<td></td>
<td></td>
<td>0.09</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>48 (84)</td>
<td>28 (70)</td>
<td></td>
</tr>
<tr>
<td>Intraductal papillary mucinous neoplasm</td>
<td>6 (11)</td>
<td>2 (5)</td>
<td></td>
</tr>
<tr>
<td>Chronic pancreatitis</td>
<td>1 (1.8)</td>
<td>2 (5)</td>
<td></td>
</tr>
<tr>
<td>Cystadenoma (serous/mucinous)</td>
<td>0</td>
<td>3 (7.5)</td>
<td></td>
</tr>
<tr>
<td>Neuroendocrine tumour</td>
<td>1 (1.8)</td>
<td>1 (2.5)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1 (1.8)</td>
<td>4 (10)</td>
<td></td>
</tr>
<tr>
<td>Tumour limited to the pancreas b, n (%)</td>
<td>6 (12)</td>
<td>5 (15)</td>
<td>0.72</td>
</tr>
<tr>
<td>Tumour extending beyond the pancreas b, n (%)</td>
<td>44 (88)</td>
<td>29 (85)</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis c, n (%)</td>
<td>37 (74)</td>
<td>27 (79)</td>
<td>0.57</td>
</tr>
<tr>
<td>Unilateral adrenalectomy, n (%)</td>
<td>5 (8.8)</td>
<td>0 (0)</td>
<td>0.05</td>
</tr>
</tbody>
</table>

SD = standard deviation.

a) Alcohol consumption exceeding the recommendation of The Danish Health Authority (women: 7 U/wk, men: 14 U/wk).

b) Tumour staging was performed in 50 and 34 patients, tumour staging included T1 and T2 or T3 and T4, staging according to the American Joint Committee on Cancer TNM staging system.
Outcome measures
The primary outcome was glycaemic control, evaluated by distribution of plasma glucose levels < 4.0 mmol/l, 4.0-10.0 mmol/l or > 10.0 mmol/l, and length of hospitalisation. Secondary outcome measures were incidence of complications within the first 13 post-operative days.

Statistical analysis
Numerical variables are presented as mean ± standard deviation when regarded normally distributed, otherwise as median and range. Dichotomous variables are presented as numbers and percentages. Student’s t test, the Mann-Whitney U-test and the chi-squared test were used as appropriate. p-values < 0.05 were considered significant. Statistical analyses were performed using SPSS Statistics 22 (IBM, Armonk, NY, USA).

Trial registration: not relevant.

RESULTS
Study population
The demographic and clinical characteristics of the two cohorts including tumour staging were comparable, with the exception that preoperative diabetes occurred less frequently in the PN cohort than in the glucose cohort (p = 0.04) (Table 1). In the glucose cohort, 11 (28%) patients received PN with a median duration of three days within the first 13 post-operative days in addition to glucose infusion, mostly in cases where post-operative complications caused a delay in achieving a sufficient oral intake.

Glycaemic control
In the PN cohort, 3,312 plasma glucose measurements were registered during 754 observation days. Similarly, in the glucose cohort, 2,143 plasma measurements were registered during 553 observation days.

The course of the plasma glucose followed a similar configuration throughout the post-operative period in the two cohorts, without any clinically significant differences (Figure 1). More plasma glucose measurements were within the target range 4.0-10.0 mmol/l in the PN cohort compared to the glucose cohort (p = 0.01) (Table 2) without any difference in prevalence of severe symptomatic hypoglycaemia (p = 0.10). No clinically significant weight loss was seen in either cohort (Table 2).

A sub-analysis was performed of the 32 patients who discontinued PN within the first 13 post-operative days. A pooled analysis of glucose data four days prior to and four days after discontinuation of PN revealed a median plasma glucose of 12.2 mmol/l and 8.4 mmol/l before and after discontinuation of PN, respectively (p < 0.001) (Figure 2). The prevalence of biochemical hypoglycaemia (< 4.0 mmol/l) was 0.7% out of 613 measurements before and 7.0% out of 591 measurements after discontinuation of PN (p < 0.001).

Post-operative complications
There were fewer non-infectious complications in the PN cohort than in the glucose cohort (23% versus 43%, p = 0.04), with wound dehiscence being the most prevalent complication in both groups. There was a smaller number of infectious complications and major complications in the PN cohort than in the glucose cohort, but the differences did not reach statistical significance. One patient in each cohort died within the first 14 days dur-
Intraoperative image during total pancreatectomy.

We found a trend towards decreased prevalence of sepsis and other infectious complications during PN. This may be owed to the improved nutrition including additional carbohydrate, protein and lipids within the first eight post-operative days in the PN cohort. Supplementary protein intake in the post-operative period has previously been shown to decrease the incidence of minor complications following surgery including wound infection [13]. However, our results contradict a previous literature review concluding that PN increases the risk of infectious post-operative complications [11]. Additionally, in one study, patients who underwent partial pancreatectomy had a significant increase in infectious complications when receiving PN [14]. However, these results may not be representative for the patients in the present study because, unlike patients undergoing total pancreatectomy, patients with partial pancreatectomy maintain endogenous glucagon and insulin production. The reduced number of non-infectious complications in the PN cohort could be a result of the improved post-operative nutritional status and higher levels of circulating insulin in these vulnerable patients. We registered a shorter length of hospitalisation in the PN cohort than in the glucose cohort. However, this finding was not statistically significant, which might be due to the relatively small number of patients in the present study.

The glycaemic control during transition from PN to oral nutrition is also described in this paper. Initiation of oral nutrition post-operatively is often complicated by nausea, vomiting, and diarrhoea, which may result in a limited food intake and increase the risk of hypoglycaemia. To overcome this increased risk of hypoglycaemia, the long-acting insulin detemir with low day-to-day variability [15] was administered twice daily with a relatively low evening dose. Despite this strategy, the prevalence of hypoglycaemia rose tenfold when PN was discontinued, and reduction of the evening basal insulin dose was often necessary. At discharge, the total insulin dose was 22 IU/day corresponding to approximately 0.3 IU/kg/day, i.e. roughly half of the requirements of patients with Type 1 diabetes. This is in accordance with previous observations in patients after total pancreatectomy [1].

The use of continuous glucose infusion as the primary nutritional support before 2012 was based on the ASPEN guidelines and the expectation that most patients were able to initiate oral feeding within few days. However, our data demonstrate that sufficient oral feeding could not be expected within seven days, which supports the implementation of PN after total pancreatectomy.

The sample size in this study was large for this rare type of surgery [1, 2, 5, 16-20]. All patients were treated by the same two surgeons, who used the same surgical
technique, which minimised the risk that a difference in the number of post-operative complications was a result of variation in the surgeons’ experience with the surgical procedure. Both cohorts were treated according to the same antibiotic regimen. All data were extracted and analysed according to a predefined protocol, and data regarding the primary outcomes were deemed accessible and reliable. In this retrospective study, data relied on information collected from medical and surgical records, so other causes for the decline in post-operative complications cannot be excluded. The number of readmissions was low in both cohorts, and larger studies are needed to evaluate any differences in readmission rate. Mortality during the first 13 post-operative days was comparable, and data on long-term survival were not included. The higher rate of preoperative diabetes in the glucose cohort might reflect a decreased peripheral insulin sensitivity leading to higher plasma glucose levels. Previously, total pancreatectomy was discredited and nearly abandoned because of morbidity and mortality due to unstable plasma glucose values [18]. The present study and recent studies [17-19] indicate that total pancreatectomy can be performed safely when PN in combination with modern diabetes treatment is offered. Information from this study, which includes a detailed insulin protocol, may be of importance for future treatment of patients after total pancreatectomy.

CONCLUSIONS
After total pancreatectomy, PN with insulin per protocol improves glycaemic control compared to intravenous glucose infusion and reduces the number of non-infectious post-operative complications. Importantly, treatment with PN does not increase the number of infectious post-operative complications or hypoglycaemia.

CORRESPONDENCE: Sakshi Andersen. E-mail: saks88@gmail.com

ACCEPTED: 14 February 2018

CONFLICTS OF INTEREST: Disclosure forms provided by the authors are available with the full text of this article at www.danmedj.dk

ACKNOWLEDGEMENTS: *) Sakshi Andersen and Andreas Andersen contributed equally to this study.

LITERATURE